These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 8251105)
21. Communicating with the FDA: the "third rail" of a new model for drug development. Stanski DR; Orloff JJ J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890 [No Abstract] [Full Text] [Related]
22. They are from the government and they really are here to help you. Woosley RL J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889 [No Abstract] [Full Text] [Related]
23. Assuring the quality, safety, and efficacy of DNA vaccines. Robertson JS; Griffiths E Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466 [TBL] [Abstract][Full Text] [Related]
24. Accelerated approval and oncology drug development timelines. Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846 [No Abstract] [Full Text] [Related]
27. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe. Porter RJ; Baulac M; Nohria V Epilepsy Res; 2010 May; 89(2-3):163-75. PubMed ID: 20347575 [TBL] [Abstract][Full Text] [Related]
28. Review of the newer antiepileptic drugs. Tidwell A; Swims M Am J Manag Care; 2003 Mar; 9(3):253-76; quiz 277-9. PubMed ID: 12643343 [TBL] [Abstract][Full Text] [Related]
29. Fostering the relationship between the clinical research associate and the drug study coordinator. Brodie MA Epilepsy Res Suppl; 1993; 10():233-7. PubMed ID: 8251101 [No Abstract] [Full Text] [Related]
30. Evaluating a new protocol from the investigator's perspective. Wilder BJ; Hargrove SC Epilepsy Res Suppl; 1993; 10():181-4. PubMed ID: 8251094 [No Abstract] [Full Text] [Related]
31. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
32. Testing antiepileptic drugs in children. French JA; Leppik I J Child Neurol; 1994 Oct; 9 Suppl 1():S26-32. PubMed ID: 7822749 [TBL] [Abstract][Full Text] [Related]
33. [From molecule to medicine--drug development]. Bruhn C Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355 [No Abstract] [Full Text] [Related]
34. The needs of the few. Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796 [No Abstract] [Full Text] [Related]
35. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development. Milton MN; Horvath CJ Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571 [No Abstract] [Full Text] [Related]
36. The problem of new uses. Eisenberg RS Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897 [No Abstract] [Full Text] [Related]
37. Closing a loophole in the FDA Amendments Act. Turner EH Science; 2008 Oct; 322(5898):44-6. PubMed ID: 18832629 [No Abstract] [Full Text] [Related]
38. US court rules to allow experimental drugs for dying patients. Waltz E Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988 [No Abstract] [Full Text] [Related]
39. What's the problem with generic antiepileptic drugs?: a call to action. Berg MJ Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211 [No Abstract] [Full Text] [Related]
40. Issues in the treatment of epilepsy. Leppik IE Epilepsia; 2001; 42 Suppl 4():1-6. PubMed ID: 11564117 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]